BPC-157: What the Research Shows
For laboratory and research use only. This article summarises published scientific research on BPC-157. Neurovia’s BPC-157 is not intended for human consumption, diagnosis, or treatment of any condition. See our disclaimer.
BPC-157: What the Research Shows
BPC-157 is one of the most researched synthetic peptides in preclinical science. First described in the published literature in the 1990s, it has since accumulated a substantial body of peer-reviewed research across multiple biological systems.
This article provides an evidence-based overview of BPC-157: its molecular identity, the published research landscape, stability characteristics, and supply format for laboratory use.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a peptide consisting of 15 amino acids. Its amino acid sequence is:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
BPC-157 is a partial sequence derived from a larger protein found in gastric juice, though the 15-amino acid synthetic compound studied in research does not occur naturally in this exact form. It was developed and extensively researched by a team at the University of Zagreb, with Professor Predrag Sikiric as the principal investigator across decades of published work.
Molecular formula: C₆₂H₁₀₀N₁₆O₂₂
Molecular weight: 1419.5 g/mol
CAS Number: 137525-51-0
The Published Research Landscape
BPC-157 has been the subject of a large number of preclinical studies, predominantly in rodent models, investigating its effects across several biological systems. The research is primarily from the University of Zagreb group, with additional independent studies from other institutions.
Gastrointestinal Research
The earliest and most extensive BPC-157 research centres on the gastrointestinal system. Published studies have investigated its interactions with gastric tissue in rodent models, including its studied relationship with mucosal integrity and the gut-brain axis.
Key publications include work by Sikiric et al. published in journals including Current Pharmaceutical Design, Journal of Physiology and Pharmacology, and World Journal of Gastroenterology, spanning from the mid-1990s through to recent years.
Tendon and Musculoskeletal Research
A significant body of published research has examined BPC-157 in the context of tendon and connective tissue in animal models. Studies have investigated its interactions with growth factor expression — particularly studies examining VEGF (vascular endothelial growth factor) and related angiogenic pathways in tissue repair contexts.
Published work includes studies in rodent models examining Achilles tendon, muscle tissue, and bone healing contexts, predominantly from the Zagreb group and published in journals including Journal of Orthopaedic Research.
Neurological Research
A smaller body of published research has investigated BPC-157 in neurological contexts in animal models, including studies examining dopaminergic and serotonergic pathways, and interactions with the nitric oxide (NO) system.
Cardiovascular Research
Published studies have examined BPC-157 in cardiovascular contexts in rodent models, including research on vasodilation mechanisms and interactions with the nitric oxide synthase system.
Mechanism of Action: What the Research Proposes
The precise mechanism through which BPC-157 exerts its studied effects remains an area of active investigation. Published research has proposed several pathways:
Nitric oxide (NO) system interactions — Multiple published studies suggest BPC-157 interacts with the NO system, with some research proposing modulation of nitric oxide synthase activity as a component of its observed effects in animal models.
Growth factor interactions — Studies have investigated BPC-157’s relationship with VEGF expression and FAK (focal adhesion kinase) signalling, which are implicated in tissue repair and angiogenesis research.
Receptor interactions — Research has proposed interactions with the growth hormone receptor pathway, though the specific binding mechanisms are not fully characterised in the published literature.
It is important to note that the majority of published mechanistic research has been conducted in vitro or in rodent models. Extrapolation of these findings to human biology requires clinical investigation, which has not been completed for BPC-157 as of the time of writing.
BPC-157 Stability
BPC-157 exhibits notable stability characteristics that have been documented in the published research, and which distinguish it from some other research peptides.
In lyophilised form, BPC-157 is highly stable and resistant to degradation when stored correctly (see storage section below). The peptide’s structure is relatively resistant to enzymatic degradation compared to many other peptides studied in similar contexts.
In solution, BPC-157 maintains stability under acidic conditions, which is relevant to its studied interactions with the gastric environment in preclinical research. Stability in neutral to alkaline solutions is lower.
BPC-157 peptide structure and stability data are available in the primary published literature, including characterisation studies from the Zagreb research group.
For research purposes, lyophilised storage at -20°C is recommended to maintain long-term stability. Once reconstituted, the solution should be stored at 2–8°C and used within 4 weeks.
BPC-157 Research Supply Format
For laboratory research, BPC-157 is typically supplied as a lyophilised white to off-white powder in sealed vials.
Neurovia supplies BPC-157 in the following research formats:
- BPC-157 10mg vial (lyophilised)
- BPC-157 Capsules 500mcg
- BPC-157 / TB-500 Blend (lyophilised, 1mg capsule format)
- BPC Wolverine series (multi-peptide blends including BPC-157 with MGF and/or KPV)
All supplied at 99% purity, third-party tested, with Certificate of Analysis available.
BPC-157 in the Context of Other Peptide Research
BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4) in preclinical research, as the two peptides have been investigated in overlapping biological contexts — particularly in the area of tissue repair research. Some published studies have examined them in combination in animal models.
The BPC-157 / TB-500 research combination is one of the most commonly referenced in the preclinical peptide literature, which is reflected in the availability of blend formats from research suppliers.
Current Status of BPC-157 Research
As of 2026, BPC-157 remains a research compound without approved pharmaceutical status in any major regulatory jurisdiction. It is not approved by the FDA for human therapeutic use, nor has it completed clinical trials.
The published research base is predominantly preclinical (animal studies and in vitro work). While this provides a substantial mechanistic and exploratory foundation, it does not constitute evidence of safety or efficacy in humans.
Research interest in BPC-157 remains active, with new publications appearing regularly in peer-reviewed journals.
Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid research peptide derived from a sequence found in gastric juice. It has been extensively studied in preclinical animal models across gastrointestinal, musculoskeletal, neurological, and cardiovascular research contexts.
What research has been done on BPC-157?
The majority of BPC-157 research has been conducted by a team at the University of Zagreb, led by Professor Predrag Sikiric, published across multiple peer-reviewed journals since the mid-1990s. Research has covered gastrointestinal, tendon/connective tissue, neurological, and cardiovascular contexts in animal models.
What is the molecular structure of BPC-157?
BPC-157 is a 15-amino acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular formula is C₆₂H₁₀₀N₁₆O₂₂ and molecular weight is approximately 1419.5 g/mol.
How stable is BPC-157?
In lyophilised form, BPC-157 is highly stable when stored at -20°C. In solution, it is more stable under acidic conditions. Once reconstituted, it should be refrigerated and used within 4 weeks.
Is BPC-157 approved for human use?
No. BPC-157 is not approved by the FDA or any major regulatory agency for human therapeutic use. It is a research compound available for laboratory and preclinical research purposes only.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino acid synthetic peptide studied primarily in gastrointestinal and tissue repair contexts. TB-500 is a synthetic analogue of Thymosin Beta-4, an actin-binding protein. Both have been studied in tissue repair research contexts in animal models, and some studies have examined them in combination.
What is the BPC-157 peptide structure?
BPC-157 consists of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its structure includes a notable proline-rich central region that is associated with its stability characteristics in the published research.
How is BPC-157 supplied for research?
BPC-157 is typically supplied as a lyophilised powder in sealed vials at ≥98–99% purity, with a Certificate of Analysis from a third-party laboratory confirming identity and purity.
This article summarises published peer-reviewed research on BPC-157 and is provided for informational purposes only. It does not constitute medical advice, and Neurovia’s BPC-157 is supplied for laboratory research use only. It is not intended for human consumption, diagnosis, treatment, or prevention of any condition. Full disclaimer →